Benchmark Radar™
Star —

OncoTraj Benchmark

Explore score history ↗

OncoTraj is a public benchmark for predicting acquired resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer. It provides a harmonized dataset of 813 patients from three real-world sources, with locked splits, an evaluation harness, and six baselines, defining three tasks: 12-month progression classification, time-to-progression regression, and resistance mechanism classification.

Released
2026-06-09
Evaluates
Biology & Drug Discovery, Language & Knowledge, cs.LG
Openness
unknown
Importer
Claire Radar
Review status
unreviewed

OncoTraj paper, code and dataset

No reported scores are on record for this benchmark yet.

Which sources cite OncoTraj?

Related Biology & Drug Discovery, Language & Knowledge, cs.LG benchmarks